Literature DB >> 10103016

Oligonucleotide aggregates bind to the macrophage scavenger receptor.

K Suzuki1, T Doi, T Imanishi, T Kodama, T Tanaka.   

Abstract

We have prepared a model receptor containing a Lys cluster (320-340) in the collagen-like domain of the bovine macrophage scavenger receptor, and have shown that it has a similar binding specificity to the native scavenger receptor. The native scavenger receptor is reported to bind the quadruplex structure of nucleotides. In this study, we analyzed the model receptor binding of nucleotides with various structures, random, parallel or antiparallel quadruplex and aggregate forms. This was carried out by direct binding assays using labeled oligonucleotides or surface plasmon resonance, and by an inhibition assay using Chinese hamster ovary (CHO) cells expressing the scavenger receptor. The results showed that the nucleotides forming the quadruplex structure did not exhibit any binding. Only the aggregate forms of the nucleotide could bind to the model receptor. They also inhibited the degradation of acetylated low density lipoprotein by CHO cells expressing the native scavenger receptor, whereas nucleotides that did not bind to the model receptor had no effect on cellular acetylated low density lipoprotein degradation. Our results suggest that the quadruplex structure is not essential but may be required for the formation of the nucleotide aggregates, which can interact with the scavenger receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10103016     DOI: 10.1046/j.1432-1327.1999.00233.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  8 in total

Review 1.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

2.  The role of the macrophage scavenger receptor in immune stimulation by bacterial DNA and synthetic oligonucleotides.

Authors:  F G Zhu; C F Reich; D S Pisetsky
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

3.  Differential cytokine production and bystander activation of autoreactive B cells in response to CpG-A and CpG-B oligonucleotides.

Authors:  Ana M Avalos; Eicke Latz; Betty Mousseau; Sean R Christensen; Mark J Shlomchik; Frances Lund; Ann Marshak-Rothstein
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422

4.  TARGETING OF MACROPHAGE FOAM CELLS IN ATHEROSCLEROTIC PLAQUE USING OLIGONUCLEOTIDE-FUNCTIONALIZED NANOPARTICLES.

Authors:  Gaurav Sharma; Zhi-Gang She; David T Valenta; William B Stallcup; Jeffrey W Smith
Journal:  Nano Life       Date:  2010-09

5.  Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging.

Authors:  Prabuddha Mukherjee; Edita Aksamitiene; Aneesh Alex; Jindou Shi; Kajari Bera; Chi Zhang; Darold R Spillman; Marina Marjanovic; Michael Fazio; Punit P Seth; Kendall Frazier; Steve R Hood; Stephen A Boppart
Journal:  Nucleic Acid Ther       Date:  2021-11-19       Impact factor: 4.244

6.  Plaque-Targeted Rapamycin Spherical Nucleic Acids for Synergistic Atherosclerosis Treatment.

Authors:  Yuanyuan Guo; Jingcan Qin; Qianqian Zhao; Jiapei Yang; Xiaoer Wei; Yu Huang; Miao Xie; Chuan Zhang; Yuehua Li
Journal:  Adv Sci (Weinh)       Date:  2022-03-28       Impact factor: 17.521

7.  Defining the Design Parameters for in Vivo Enzyme Delivery Through Protein Spherical Nucleic Acids.

Authors:  Caroline D Kusmierz; Katherine E Bujold; Cassandra E Callmann; Chad A Mirkin
Journal:  ACS Cent Sci       Date:  2020-04-27       Impact factor: 14.553

Review 8.  Spherical Nucleic Acids as Precision Therapeutics for the Treatment of Cancer-From Bench to Bedside.

Authors:  Akanksha S Mahajan; Alexander H Stegh
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.